Indications for imatinib mesylate therapy and clinical management.

@article{Guilhot2004IndicationsFI,
  title={Indications for imatinib mesylate therapy and clinical management.},
  author={François Guilhot},
  journal={The oncologist},
  year={2004},
  volume={9 3},
  pages={271-81}
}
Imatinib mesylate (Gleevec), Glivec, formerly STI571; Novartis Pharma AG; Basel, Switzerland) is a rationally-designed, molecularly-specific oral anticancer agent that selectively inhibits several protein tyrosine kinases central to the pathogenesis of human cancer. It has demonstrated remarkable clinical efficacy in patients with chronic myeloid leukemia and malignant gastrointestinal stromal tumors. Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects… CONTINUE READING